AUBAGIO

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug AUBAGIO contains one active pharmaceutical ingredient (API):

1 Teriflunomide
UNII 1C058IKG3B - TERIFLUNOMIDE

Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes.

Read about Teriflunomide

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
AUBAGIO Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AK02 L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AK
Discover more medicines within L04AK02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 2898M
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 502818120078517, 576720020052817
Country: CA Health Products and Food Branch Identifier(s): 02416328
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 470-MEE-1014
Country: EE Ravimiamet Identifier(s): 1619579, 1624081, 1624092, 1624104, 1624115, 1670813, 1851511
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 113838002, 113838002IP
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 061112, 108819
Country: FR Base de données publique des médicaments Identifier(s): 62160702
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 245047
Country: HK Department of Health Drug Office Identifier(s): 63504
Country: IE Health Products Regulatory Authority Identifier(s): 88698
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7381
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1071145, 1071146, 1071147, 1071148, 1071149, 1092835
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 148M2013
Country: NL Z-Index G-Standaard, PRK Identifier(s): 117838
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 15732
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100304493, 100451802
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W69302001, W69302002, W69302003, W69302004, W69302005, W69303001
Country: SG Health Sciences Authority Identifier(s): 14841P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 16283011H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699809098541
Country: US FDA, National Drug Code Identifier(s): 58468-0210, 58468-0211
Country: ZA Health Products Regulatory Authority Identifier(s): 47/32.16/0859

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.